Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × AM0010 × Gastrointestinal × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Fluorouracil 254 Oxaliplatin 217 Leucovorin 188 Capecitabine 167 Irinotecan 115 Gemcitabine 109 Cisplatin 106 Bevacizumab 96 Radiotherapy 69 Paclitaxel 56 Folfox protocol 50 Drug Therapy 43 Cetuximab 41 Sorafenib 40 Docetaxel 37 S 1 (combination) 35 Chemotherapy, Adjuvant 34 Neoadjuvant Therapy 33 pembrolizumab 31 XELOX 23 lenvatinib 22 Surgical Procedures, Operative 22 Radiation 21 Panitumumab 20 130-nm albumin-bound paclitaxel 20 Nivolumab 19 Chemoradiotherapy 19 regorafenib 18 atezolizumab 18 trifluridine tipiracil drug combination 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02923921 2020-10-19

Sequoia

Eli Lilly and Company

Phase 3 Completed

567 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡